IDH1 and glioma: The selective synergy observed in IDH1 WT backgrounds, particularly with the compound 2/TMZ combination, suggests that IDH1 mutation status modulates the efficacy of RNaseH2 inhibition, meriting further investigation in genetic models that further reflect glioma diversity.